Evidence map›Paper›PMID 38196612›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Impaired incretin homeostasis in non-diabetic moderate-severe CKD.

Armin Ahmadi, Jorge Gamboa, Jennifer E Norman, Byambaa Enkhmaa, Madelynn Tucker, Brian J Bennett, Leila R Zelnick, Sili Fan, Lars F Berglund, Talat Alp Ikizler and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Armin AhmadiDepartment of Internal Medicine, Division of Nephrology, University of California Davis, Davis, California, USA.
Jorge GamboaDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jennifer E NormanDepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, California, USA.
Byambaa EnkhmaaDepartment of Internal Medicine, Division of Endocrinology, University of California Davis, Davis, California, USA.
Madelynn TuckerSchool of Medicine, Department of Surgery, Center for Alimentary and Metabolic Sciences, University of California, Davis, Sacramento, CA, United States.
Brian J BennettObesity and Metabolism Research Unit, Western Human Nutrition Research Center, USDA, ARS, Davis, California, USA.
Leila R ZelnickDivision of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Sili FanDepartment of Public Health Sciences, Division of Biostatistics, University of California, Davis, CA, USA.
Lars F BerglundDepartment of Internal Medicine, University of California, Davis, CA, USA.
Talat Alp IkizlerDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ian H de BoerDivision of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Bethany P CummingsSchool of Medicine, Department of Surgery, Center for Alimentary and Metabolic Sciences, University of California, Davis, Sacramento, CA, United States.
Baback RoshanravanDepartment of Internal Medicine, Division of Nephrology, University of California Davis, Davis, California, USA.
University of California, Davis · USUniversity of Washington · USVanderbilt University Medical Center · USWestern Human Nutrition Research Center · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI REBECCA LUCY HULL-MEICHLE · 1986 to 2026
$41.4M
Role of Mitochondrial Dysfunction in the Response to Exercise in Patients with Advanced Kidney DiseaseR01DK125794 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAMBOA, JORGE LUIS, IKIZLER, TALAT ALP · 2021 to 2025
$3.3M
Impact of metabolic acidosis on muscle mitochondrial energetics, metabolic health and physical endurance in persons with chronic kidney diseaseR01DK129793 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ROSHANRAVAN, BABACK · 2021 to 2025
$3.2M
Insulin Resistance in Chronic Kidney DiseaseR01DK087726 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2013
$1.9M
Patient Oriented Research In Clinical NutritionK24DK096574 · NIDDK · EMORY UNIVERSITY · PI ZIEGLER, THOMAS R · 2012 to 2016
$888k
Integration of Nutritional Metabolomics with Bioenergetics in Cystic FibrosisK01DK102851 · NIDDK · EMORY UNIVERSITY · PI ALVAREZ, JESSICA ALEJANDRA · 2014 to 2018
$614k
Defining alpha-cell proglucagon processing for type 2 diabetes treatmentR56DK124853 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CUMMINGS, BETHANY PAIGE · 2020 to 2020
$387k
NIDDK NIH HHS K01 DK102851NIDDK NIH HHS K24 DK096574NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK087726NIDDK NIH HHS R01 DK125794NIDDK NIH HHS R01 DK129793NIDDK NIH HHS R56 DK124853
6 · The paper itself

Abstract

Background: Incretins are regulators of insulin secretion and glucose homeostasis that are metabolized by dipeptidyl peptidase-4 (DPP-4). Moderate-severe CKD may modify incretin release, metabolism, or response. Methods: We performed 2-hour oral glucose tolerance testing (OGTT) in 59 people with non-diabetic CKD (eGFR<60 ml/min per 1.73 m Results: Mean eGFR was 38 ±13 and 89 ±17ml/min per 1.73 m Conclusion: Incretin response to oral glucose is preserved or augmented in moderate-severe CKD, without apparent differences in circulating DPP-4 concentration or activity. However, neither insulin secretion nor glucagon suppression are enhanced.

Identifiers

PMID38196612
PMCPMC10775324
OpenAlexW4389953164

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.